Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: A cost-effectiveness analysis for Germany;Pegfilgrastim vs. Filgrastim zur Primärprophylaxe der febrilen Neutropenie bei Brustkrebspatientinnen nach Chemotherapie: Eine Kosten-Effektivitäts-Analyse für Deutschland

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 9, 2010, Pages 385-389

  Sehouli, J ^a   Goertz, A ^b   Steinle, T ^b   Dubois, R ^c   Plesnila Frank, C ^d   Lalla, A ^c   Von Minckwitz, G ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Amgen Research GmbH   (Germany)

^c CERNER CORPORATION   (United States)

^d IQVIA   (United States)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Breast cancer; Cost effectiveness; Febrile neutropenia; Filgrastim; Granulocyte colony stimulating factor (G CSF); Pegfilgrastim

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; GERMANY; HEALTH CARE COST; HUMAN; MULTIPLE CYCLE TREATMENT; PRIMARY PREVENTION; QUALITY OF LIFE; SINGLE DRUG DOSE; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; FEVER OF UNKNOWN ORIGIN; FILGRASTIM; GERMANY; HUMANS; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NEOPLASM STAGING; NEUTROPENIA; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS;

EID: 77649126999     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1249174     Document Type: Article

References (36)

1. Armstrong K, Chen T M., Albert D, Randall T C., Schwartz J S. Cost-Effectiveness of Raloxifene and Hormone Replacement Therapy in Postmenopausal Women: Impact of Breast Cancer Risk. Obstet Gynecol 2001 98 996-1003
2. Bonadonna G, Moliterni A, Zambetti M, Daidone M G., Pilotti S, Gianni L, Valagussa P. 30 Years Follow Up of Randomised Studies of Adjuvant CMF in Operable Breast Cancer: Cohort Study. BMJ 2005 330 217
3. Bonadonna G, Valagussa P. Dose-Response Effect of Adjuvant Chemotherapy in Breast Cancer. N Engl J Med 1981 304 10-15
4. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer: the Results of 20 Years of Follow-Up. N Engl J Med 1995 332 901-906
5. Brown R E., Hutton J. Cost-Utility Model Comparing Docetaxel and Paclitaxel in Advanced Breast Cancer Patients. Anticancer Drugs 1998 9 899-907
6. Brown R E., Hutton J, Burrell A. Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK. Pharmacoeconomics 2001 19 1091-1102
7. Caggiano V, Weiss R V., Rickert T S., Linde-Zwirble W T. Incidence, Cost, and Mortality of Neutropenia Hospitalization Associated With Chemotherapy. Cancer 2005 103 1916-1924
8. Colleoni M, Li S, Gelber R D., Price K N., Coates A S., Castiglione-Gertsch M, Goldhirsch A. Relation Between Chemotherapy Dose, Oestrogen Receptor Expression, and Body-Mass Index. Lancet 2005 366 1108-1110
9. Crawford J, Caserta C, Roila F. Hematopoietic Growth Factors: ESMO Recommendations for the Applications. Ann Oncol 2009 20 Suppl 4 162-165
10. Crawford J, Dale D C., Lyman G H. Chemotherapy-Induced Neutropenia: Risks, Consequences, and New Directions for Its Management. Cancer 2004 100 228-237
11. Deutsche Krankenhausgesellschaft. Tarif Der Deutschen Krankenhausgesellschaft Zugleich BG-T Vereinbarter Tarif Für Die Abrechnung Mit Den Gesetzlichen Unfallversicherugsträgern. 30 aktualisierte Auflage, ed. Stuttgart Kohlhammer Verlag 2005
12. GENACTIS. Market Research Results. http://www.genactis.com 2006
13. Hannover Consensus Group German Recommendations on Health Economic Evaluation Studies. Revised Version of Hannover Consensus., 95 ed.; 2000 52-55
14. Hershman D, McBride R, Jacobson J S., Lamerato L, Roberts K, Grann V R., Neugut A I. Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer. J Clin Oncol 2005 23 6639-6646
15. Hillner B E., Smith T J., Desch C E. Efficacy and Cost-Effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer. Estimates Using Decision Analysis While Awaiting Clinical Trial Results. JAMA 1992 267 2055-2061
16. Institut für das Entgeltsystem im Krankenhaus gGmbH (InEK gGmbH). Fallpauschalenkatalog, G-DRG-Version. http://www.gdrg.de/service/download/ veroeff 2005 2006
17. Kuderer N M., Dale D C., Crawford J, Lyman G H. Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: a Systematic Review. J Clin Oncol 2007 25 3158-3167
18. Landtag Nordrhein-Westfalen. Situation Und Zukunft Der Pflege in NRW Bericht Der Enquete-Kommission Des Landtags Von Nordrhein-Westfalen. http://www.landtag-nrw.de 2005
19. Lauer-Fischer GmbH, Fürth. Lauer Taxe. http://www.lauer-fischer.de 2008
20. Leonard R C., Miles D, Thomas R, Nussey F. Impact of Neutropenia on Delivering Planned Adjuvant Chemotherapy: UK Audit of Primary Breast Cancer Patients. Br J Cancer 2003 89 2062-2068
21. Liljegren G, Karlsson G, Bergh J, Holmberg L. The Cost-Effectiveness of Routine Postoperative Radiotherapy After Sector Resection and Axillary Dissection for Breast Cancer Stage I. Results From a Randomized Trial. Ann Oncol 1997 8 757-763 (Pubitemid 27397899)
22. Liu Z, Doan Q V., Malin J, Leonard R. The Economic Value of Primary Prophylaxis Using Pegfilgrastim Compared With Filgrastim in Patients With Breast Cancer in the UK. Appl Health Econ Health Policy 2009 7 193-205
23. Lyman G H., Crawford J, Dale D C. Clinical Prediction Models for Febrile Neutropenia (FN) and Relative Dose Intensity (RDI) in Patients Receiving Adjuvant Breast Cancer Chemotherapy [abstract]. Proc Am Soc Clin Oncol 2001 20
24. Lyman G H. Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors With Cancer Chemotherapy: a Review of the Evidence. J Natl Compr Canc Netw 2005 3 557-571
25. Lyman G H., Dale D C., Crawford J. Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: a Nationwide Study of Community Practices. J Clin Oncol 2003 21 4524-4531
26. Lyman G H., Kuderer N M. The Economics of the Colony-Stimulating Factors in the Prevention and Treatment of Febrile Neutropenia. Crit Rev Oncol Hematol 2004 50 129-146
27. Lyman G H., Lalla A, Barron R L., Dubois R W. Cost-Effectiveness of Pegfilgrastim Versus Filgrastim Primary Prophylaxis in Women With Early-Stage Breast Cancer Receiving Chemotherapy in the United States. Clin Ther 2009 31 1092-1104
28. Martin M, Lluch A, Segui M A., Ruiz A, Ramos M, Adrover E, Rodriguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacon C, et al. Toxicity and Health-Related Quality of Life in Breast Cancer Patients Receiving Adjuvant Docetaxel, Doxorubicin, Cyclophosphamide (TAC) or 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC): Impact of Adding Primary Prophylactic Granulocyte-Colony Stimulating Factor to the TAC Regimen. Ann Oncol 2006 17 1205-1212
29. Minckwitz G von, Kummel S, du Bois, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa S D., Jackisch C, et al. Pegfilgrastim +/- Ciprofloxacin for Primary Prophylaxis With TAC (Docetaxel/Doxorubicin/ Cyclophosphamide) Chemotherapy for Breast Cancer. Results From the GEPARTRIO Study. Ann Oncol 2008 19 292-298
30. Morrow T, Siegel M, Boone S, Lawless G, Carter W. Chemotherapy Dose Intensity Determination As a Quality of Care Measure for Managed Care Organizations in the Treatment of Early-Stage Breast Cancer. Am J Med Qual 2002 17 218-224
31. Robert Koch Institut, Berlin. Altersverteilung Von Inzidenz Und Mortalität. http://www.rki.de 2003
32. Siena S, Piccart M J., Holmes F A., Glaspy J, Hackett J, Renwick J J. A Combined Analysis of Two Pivotal Randomized Trials of a Single Dose of Pegfilgrastim Per Chemotherapy Cycle and Daily Filgrastim in Patients With Stage II-IV Breast Cancer. Oncol Rep 2003 10 715-724
33. Statistisches Bundesamt. Todesursachenstatistik. http://www.gbe-bund.de 2004
34. Timmer-Bonte J N., Adang E M., Smit H J., Biesma B, Wilschut F A., Bootsma G P., de Boo T M., Tjan-Heijnen V C. Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis With Antibiotics in Small-Cell Lung Cancer. J Clin Oncol 2006 24 2991-2997
35. Tumorregister München. Mortalitätsdaten. http://www.krebsinfo. de 2007
36. Weycker D, Hackett J, Edelsberg J S., Oster G, Glass A G. Are Shorter Courses of Filgrastim Prophylaxis Associated With Increased Risk of Hospitalization? Ann Pharmacother 2006 40 402-407